Shattuck Labs presents updated preclinical data on GADLEN plarform

Shattuck Labs announced preclinical data from the company’s novel GADLEN platform at the 2022 SITC Annual Meeting. Details of the presentation are as follows: Abstract title: Antigen targeted butyrophilin heterodimer-based bispecific engagers induce T cell-mediated anti-tumor activity Shattuck presented preclinical data highlighting the potential of GADLENs to direct Vgamma9delta2+ T cells to kill tumor cells. The bispecific GADLENs, which contain heterodimeric BTN2A1 and BTN3A1 extracellular domains fused via inert Fc linkers to scFv domains, targeting CD20 or B7-H3 antigens, demonstrated cytotoxic ability in coculture with Vgamma9delta2+ T cells. CD20-directed GADLENs enhanced the specific killing of lymphoma cells and healthy B cells that express the antigen, while B7H3-directed GADLEN increased the killing of B7-H3 expressing tumor cells. These studies shed light on the modularity of the GADLEN platform and the tumor cell markers which are important for the therapeutic activity of gamma delta T cell-based engager therapies.